PRAMIPEXOLE DIHYDROCHLORIDE
Clinical safety rating: safe
Animal studies have demonstrated safety
Non-ergoline dopamine agonist that selectively binds to D2 and D3 dopamine receptors, particularly D3, in the striatum and substantia nigra, mimicking dopamine's effects to improve motor function in Parkinson's disease.
| Metabolism | Minimally metabolized via CYP450 enzymes; less than 10% metabolized, primarily by CYP1A2. Major route is renal excretion of unchanged drug. |
| Excretion | Renal: ~90% unchanged in urine; biliary/fecal: ~2%. |
| Half-life | Terminal half-life: 8–12 hours in young adults; up to 15–18 hours in elderly. Clinical context: Once-daily dosing; steady-state in 2–4 days. |
| Protein binding | 15% bound, primarily to albumin. |
| Volume of Distribution | Vd: 3–7 L/kg; indicates extensive tissue distribution. |
| Bioavailability | Oral: >90% (immediate-release); sustained-release ~100% relative to immediate-release. |
| Onset of Action | Oral: 1–3 hours for symptomatic relief in Parkinson’s disease. |
| Duration of Action | Approximately 8–12 hours; sustained-release formulation extends to 24 hours. |
0.125 mg orally three times daily, titrated as tolerated to maximum 4.5 mg/day
| Dosage form | TABLET |
| Renal impairment | CrCl >60 mL/min: no adjustment; CrCl 35–60 mL/min: initial 0.125 mg twice daily, max 3.75 mg/day; CrCl 15–34 mL/min: initial 0.125 mg once daily, max 2.25 mg/day; CrCl <15 mL/min: not recommended |
| Liver impairment | No specific dose adjustment required for hepatic impairment; use with caution in severe impairment |
| Pediatric use | Not established; safety and efficacy in pediatric patients (<18 years) not determined |
| Geriatric use | No specific dose adjustment; monitor for hallucinations, orthostatic hypotension, and falls; consider lower initial doses due to increased sensitivity |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Other CNS depressants may enhance sedative effects Can cause somnolence and impulse control disorders.
| Breastfeeding | Pramipexole is known to be excreted in human milk; however, the milk-to-plasma ratio (M/P) has not been established. In a study of lactating rats, pramipexole was excreted in milk at concentrations 3-4 times higher than in plasma. Due to potential for serious adverse reactions in nursing infants, including somnolence and dystonia, a decision should be made to discontinue nursing or discontinue the drug. |
| Teratogenic Risk | Pramipexole is a Pregnancy Category C drug. In animal studies, it caused post-implantation loss and decreased fetal weight at doses similar to human therapeutic doses. There are no adequate and well-controlled studies in pregnant women. First trimester risks are unknown; second and third trimester risks include potential fetal dopamine receptor modulation. Use only if potential benefit justifies potential risk. |
■ FDA Black Box Warning
No FDA black box warning.
| Common Effects | Dizziness Sleepiness Nausea Dryness in mouth Fatigue Hallucination Constipation Peripheral edema Muscle spasm |
| Serious Effects |
["Hypersensitivity to pramipexole or any component of the formulation"]
| Precautions | ["May cause orthostatic hypotension, syncope","May cause hallucinations and psychotic-like behaviors","May cause impulse control disorders (e.g., pathological gambling, hypersexuality)","May cause somnolence and sudden sleep onset episodes","May cause dyskinesia or exacerbation of Parkinson's symptoms","Risk of melanoma (unknown causal association)","Risk of fibrotic complications (e.g., pleural effusion, retroperitoneal fibrosis)","Augmentation in RLS (worsening of symptoms with long-term use)"] |
Loading safety data…
| Fetal Monitoring | Monitor for maternal hypotension, somnolence, hallucinations, and dyskinesia. Fetal monitoring should include standard prenatal care with ultrasound to assess growth and development. No specific fetal monitoring is mandated, but consider nonstress testing and biophysical profile if maternal complications arise. |
| Fertility Effects | In animal studies, pramipexole caused decreased fertility in male rats at high doses (20 mg/kg/day). In female rats, prolonged estrous cycles and reduced conception rates were observed at high doses. Human data are insufficient; however, dopamine agonists may alter prolactin levels and affect ovulation. Caution is advised in women attempting conception. |